Le Lézard
Classified in: Health, Business
Subject: LIC

Navamedic ASA acquires innovative antibiotic product for hospital use in the Nordic region


OSLO, Norway, Nov. 23, 2022 /PRNewswire/ -- Navamedic has signed an agreement with its partner InfoRLife SA (subsidiary of ACS Dobfar S.p.A.) which will expand Navamedic's portfolio of antibiotics for hospital use. Under the agreement, Navamedic acquires the rights and Marketing Authorizations for the unique Clindamycin ready-to-administer bags developed and manufactured by InfoRLife AS. Navamedic already markets Clindamycin in traditional ampoules as part of the large portfolio of antibiotics acquired from ACS Dobfar in 2020. The innovative ready-to-use product will thus complement this portfolio.

Clindamycin is a well-established antibiotic used in treatment of severe infections, including staphylococcal bone and joint infections, chronic sinusitis and infections of the lower respiratory tract. The primary benefits of this ready-to-use packaging are a reduction in medication errors, the reduced risk of contamination, storage at ambient temperature, as well as nurse time saving and a reduction of waste.

"With our efficient market access and strong local competence we launch and strive to enhance the value of products and brands, and this acquisition demonstrates how we continue to build assets of owned products. Over the recent months we have made a string of new product launches, partnerships and acquisitions, all bringing us closer to our NOK 1 billion revenue target in the mid- to long-term," says Kathrine Gamborg Andreassen, CEO of Navamedic ASA.

The Clindamycin ready-to-administer bags have been on the market in Norway, Sweden and Denmark since 2020 under the label of Villerton (owned by ACS Dobfar), mainly being sold through national and regional hospital tenders. The transfer of the marketing authorizations will be initiated within short and the product is expected to be on the market under the Navamedic label from early 2023.

For further information, please contact:

Kathrine Gamborg Andreassen, CEO, Navamedic
Mobile: +47 951 78680
E-mail: [email protected]

Lars Hjarrand, CFO, Navamedic
Mobile: +47 917 62842
E-mail: [email protected]

About Navamedic ASA:

Navamedic ASA is a Nordic pharma company and reliable provider of high-quality products, delivered to hospitals and through pharmacies, meeting the specific needs of patients and consumers by leveraging its highly scalable market access platform, leading category competence and local knowledge. Navamedic is present in all the Nordic countries, the Baltics and Benelux, with sales representation in the UK and Greece. Navamedic is headquartered in Oslo, Norway, and listed on the Oslo Stock Exchange (ticker: NAVA).

 


These press releases may also interest you

at 06:17
NEI Global Relocation's latest whitepaper, "2024 Relocation Trends | Manufacturing," provides a compelling look into how innovative relocation strategies are crucial for the manufacturing sector's talent acquisition and retention efforts. This comes...

at 06:13
JinkoSolar Holding Co., Ltd. ("JinkoSolar" or the "Company") , one of the largest and most innovative solar module manufacturers in the world, today announced that since March 20, 2024, the Company has repurchased 788,178 American depositary shares...

at 06:08
ConTemporary Locums, a physician-focused medical staffing company, is ushering in a new era with a bold rebrand: Era Locums. This brand evolution marks a commitment to continued innovation and a deeper connection with the company's physician and...

at 06:00
G-P (Globalization Partners), the recognized leader in the global employment market, and standard bearer for industry compliance, today announced it was awarded 50 leader badges in G2's 2024 Spring Report, including Employer of Record Leader, Global...

at 05:45
The Gross Law Firm issues the following notice to shareholders of New York Community Bancorp, Inc. . Shareholders who purchased...

at 05:30
Cato Networks, the SASE leader, announced a new SASE throughput record here at the Porsche Studio Ginza ahead of the 2024 Tokyo E-Prix, achieving 10 Gbps without hardware upgrades. At 10 Gbps, Cato became the first SASE platform to compete not only...



News published on and distributed by: